Literature DB >> 9526560

Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.

A Pagliara1, B Testa, P A Carrupt, P Jolliet, C Morin, D Morin, S Urien, J P Tillement, J P Rihoux.   

Abstract

The ionization and lipophilicity behavior of the antihistamine (H1-receptor antagonist) cetirizine was investigated, showing the drug to exist almost exclusively as a zwitterion in the pH region 3.5-7.5. In this pH range, its octanol/water lipophilicity is constant and low compared to cationic antihistamines (log D = log PZ = 1.5), whereas its H-bonding capacity is relatively large (delta log PZ > or = 3.1). Conformational, electronic, and lipophilicity potential calculations revealed that zwitterionic cetirizine experiences partial intramolecular charge neutralization in folded conformers of lower polarity. Pharmacokinetic investigations have shown the drug to be highly bound to blood proteins, mainly serum albumin, and to have a low brain uptake, explaining its lack of sedative effects. As such, cetirizine does not differ from "second-generation" antihistamines. In contrast, its very low apparent volume of distribution in humans (0.4 L kg-1, smaller than that of exchangeable water) implies a low affinity for lean tissues such as the myocardium and is compatible with the absence of cardiotoxicity of the drug. The zwitterionic nature and modest lipophilicity of cetirizine may account for this pharmacokinetic behavior. The suggestion is offered that cetirizine and analogous zwitterions, whose physicochemical, pharmacokinetic, and pharmacodynamic properties differ from those of "first-" and "second-generation" drugs in this class, could be considered as "third-generation" antihistamines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9526560     DOI: 10.1021/jm9704311

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

Review 1.  Cetirizine: a review of its use in children with allergic disorders.

Authors:  C M Spencer; S Noble
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 2.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Theoretical and experimental exploration of the lipophilicity of zwitterionic drugs in the 1,2-dichloroethane/water system.

Authors:  Géraldine Bouchard; Alessandra Pagliara; Pierre-Alain Carrupt; Bernard Testa; Véronique Gobry; Hubert H Girault
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

4.  Isolation and characterization of cetirizine degradation product: mechanism of cetirizine oxidation.

Authors:  Tatyana Dyakonov; April Muir; Hassen Nasri; Dana Toops; Aqeel Fatmi
Journal:  Pharm Res       Date:  2010-03-31       Impact factor: 4.200

Review 5.  Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.

Authors:  M Malik; A J Camm
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Determination of Some Non-sedating Antihistamines via Their Native Fluorescence and Derivation of Some Quantitative Fluorescence Intensity - Structure Relationships.

Authors:  Michael E El-Kommos; Samia M El-Gizawy; Noha N Atia; Noha M Hosny
Journal:  J Fluoresc       Date:  2015-10-06       Impact factor: 2.217

7.  Lipophilicity behaviour of the Zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems.

Authors:  G Plember van Balen; G Caron; G Ermondi; A Pagliara; T Grandi; G Bouchard; R Fruttero; P A Carrupt; B Testa
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

Review 8.  Clinical pharmacology of new histamine H1 receptor antagonists.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 9.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.